Starting Dose for CKD Patients on Dialysis
Aranesp (darbepoetin alfa) is given as a subcutaneous or intravenous injection once weekly or once every two weeks. For adults with chronic kidney disease (CKD) on dialysis starting or converting from epoetin alfa, the dose is 0.45 mcg/kg body weight once weekly or 0.75 mcg/kg once every two weeks.[1][2]
Starting Dose for CKD Patients Not on Dialysis
For CKD patients not on dialysis, start with 0.45 mcg/kg subcutaneously once every four weeks, or use extended dosing intervals based on hemoglobin levels and response.[1][2]
Dose Adjustments
- Target hemoglobin: 10-11 g/dL; do not exceed 11 g/dL to minimize risks like stroke or thrombosis.
- If hemoglobin rises >1 g/dL in any two-week period or exceeds 11 g/dL: Reduce dose by 25%.
- If hemoglobin <10 g/dL after 4 weeks: Increase dose by 25%.
- If hemoglobin stable for 4 weeks: Extend interval by 2-4 weeks; maximum interval is every 4 weeks.
- For conversions from epoetin alfa, use equivalent dosing tables (e.g., weekly epoetin 2500-4999 units ≈ Aranesp 6.25 mcg weekly).[1][2]
How Long Until It Works and Monitoring
Hemoglobin typically rises within 2-4 weeks. Monitor hemoglobin every 2-4 weeks initially, then every 4 weeks once stable. Iron status should be assessed; initiate or continue iron therapy if needed to support erythropoiesis.[1][2]
Special Populations
- Pediatrics (CKD on dialysis, ages 1 month+): 0.45 mcg/kg IV/SC twice weekly; adjust similarly.
- Elderly or low body weight: No specific adjustment, but monitor closely due to higher risk of cardiovascular events.
- Hepatic impairment: No dose change needed.[1][2]
Why These Doses Differ from Cancer or Chemotherapy Use
CKD dosing focuses on extended intervals (up to 4 weeks) due to slower hemoglobin decline in renal anemia, unlike shorter weekly regimens for chemotherapy-induced anemia (e.g., 2.25 mcg/kg weekly or 500 mcg fixed every 3 weeks).[1]
Common Patient Concerns with Dosing
Patients often ask about injection site pain (rotate sites: abdomen, thigh, upper arm) or forgetting doses—use reminders or prefilled syringes for home use. Overdosing risks pure red cell aplasia if antibodies develop; underdosing leads to fatigue/transfusions.[1][2]
[1]: Aranesp Prescribing Information (Amgen)
[2]: Drugs.com - Aranesp Dosage